ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FNCH Finch Therapeutics Group Inc

2.16
-0.08 (-3.57%)
Last Updated: 12:23:54
Delayed by 15 minutes

Period:

Draw Mode:

Volume 12,166
Bid Price 2.16
Ask Price 2.25
News -
Day High 2.26

Low
1.86

52 Week Range

High
16.74

Day Low 2.095
Company Name Stock Ticker Symbol Market Type
Finch Therapeutics Group Inc FNCH NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.08 -3.57% 2.16 12:23:54
Open Price Low Price High Price Close Price Prev Close
2.24 2.095 2.26 2.24
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
104 12,166 $ 2.14 $ 26,073 - 1.86 - 16.74
Last Trade Time Type Quantity Stock Price Currency
12:18:49 10 $ 2.2351 USD

Finch Therapeutics Group Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
3.47M 1.61M - 107k -74.75M -46.55 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Finch Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No FNCH Message Board. Create One! See More Posts on FNCH Message Board See More Message Board Posts

Historical FNCH Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.313.082.0952.67179,339-0.15-6.49%
1 Month2.603.371.862.77102,295-0.44-16.92%
3 Months2.724.461.862.8447,553-0.56-20.59%
6 Months3.895.701.863.0834,439-1.73-44.47%
1 Year13.2016.741.867.2245,524-11.04-83.64%
3 Years428.10663.001.8696.68156,925-425.94-99.50%
5 Years613.50675.001.86115.53158,954-611.34-99.65%

Finch Therapeutics Description

Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.

Your Recent History

Delayed Upgrade Clock